Role of the HSP90-Associated Cochaperone p23 in Enhancing Activity of the Androgen Receptor and Significance for Prostate Cancer
Open accessThe DOI matches its Crossref record, with a small difference in title or year; 65 of the 70 references it cites were found in a registry or an index.
Abstract
Prostate tumor growth initially depends on androgens, which act via the androgen receptor (AR). Despite androgen ablation therapy, tumors eventually progress to a castrate-resistant stage in which the AR remains active. The mechanisms are poorly understood but it may be that changes in levels or activity of AR coregulators affect trafficking and activation of the receptor. A key stage in AR signaling occurs in the cytoplasm, where unliganded receptor is associated with the heat shock protein (HSP)90 foldosome complex. p23, a key component of this complex, is best characterized as a cochaperone for HSP90 but also has HSP90-independent activity and has been reported as having differential effects on the activity of different steroid receptors. Here we report that p23 increases activity of the AR, and this appears to involve steps both in the cytoplasm (increasing ligand-binding capacity, possibly via direct interaction with AR) and the nucleus (enhancing AR occupancy at target promoters). We show, for the first time, that AR and p23 can interact, perhaps directly, when HSP90 is not present in the same complex. The effects of p23 on AR activity are at least partly HSP90 independent because a mutant form of p23, unable to bind HSP90, nevertheless increases AR activity. In human prostate tumors, nuclear p23 was higher in malignant prostate cells compared with benign/normal cells, supporting the utility of p23 as a therapeutic target in prostate cancer.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“PTGES3 is reported to have a cytosolic HSP90-dependent protein chaperone function for steroid nuclear receptors”
From Genome-scale CRISPR screens identify PTGES3 as a direct modulator of androgen receptor function in advanced prostate cancer (2025) · cites this paper as [41]
In the citing paper
“The proposed PGE2 enzymatic site is at the N terminus of the protein whereas the proposed HSP90 interaction motif is at the C terminus of the protein41,47.”
From Genome-scale CRISPR screens identify PTGES3 as a direct modulator of androgen receptor function in advanced prostate cancer (2025) · cites this paper as [41]
In the citing paper
“PTGES3 protein is reported to have several protein functions and to be localized to both the cytosol and nucleus41–49 (Fig. 3f).”
From Genome-scale CRISPR screens identify PTGES3 as a direct modulator of androgen receptor function in advanced prostate cancer (2025) · cites this paper as [41]
Citations
Cites
New Colorimetric Cytotoxicity Assay for Anticancer-Drug Screening
Skehan, P., Storeng, R., Scudiero, D., Monks, A., McMahon, J., Vistica, D., Warren, J. T., Bokesch, H., Kenney, S., & Boyd, M. R. (1990) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/82.13.1107 · Cited by 9,766
Nuclear Receptor Coregulators: Cellular and Molecular Biology*
McKenna, N. J., Lanz, R. B., & O’Malley, B. W. (1999) · Endocrine Reviews · doi:10.1210/edrv.20.3.0366 · Cited by 1,911
MOLECULAR CHAPERONE FUNCTIONS OF HEAT-SHOCK PROTEINS
Hendrick, J. P., & Hartl, F.-U. (1993) · Annual Review of Biochemistry · doi:10.1146/annurev.bi.62.070193.002025 · Cited by 1,638
Targeting the dynamic HSP90 complex in cancer
Trepel, J., Mollapour, M., Giaccone, G., & Neckers, L. (2010) · Nature Reviews Cancer · doi:10.1038/nrc2887 · Cited by 1,514
Métivier, R., Penot, G., Hübner, M. R., Reid, G., Brand, H., Koš, M., & Gannon, F. (2003) · Cell · doi:10.1016/s0092-8674(03)00934-6 · Cited by 1,431
The glucocorticoid receptor: rapid exchange with regulatory sites in living cells
McNally, J. G., Müller, W. G., Walker, D., Wolford, R., & Hager, G. L. (2000) · Science · doi:10.1126/science.287.5456.1262 · Cited by 802
Nuclear Receptor Coregulators: Cellular and Molecular Biology
McKenna, N. J. (1999) · Endocrine Reviews · doi:10.1210/er.20.3.321 · Cited by 782
Tanioka, T., Nakatani, Y., Semmyo, N., Murakami, M., & Kudo, I. (2000) · Journal of Biological Chemistry · doi:10.1074/jbc.m003504200 · Cited by 708 · cited 2×
“prostaglandin synthase activity (22) as well as a role in reg-”
BackgroundPratt, W. B. (1993) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(20)80556-0 · Cited by 653
Jenster, G., van der Korput, H. A. G. M., van Vroonhoven, C., van der Kwast, T. H., Trapman, J., & Brinkmann, A. O. (1991) · Molecular Endocrinology · doi:10.1210/mend-5-10-1396 · Cited by 523 · cited 1×
“The following plasmids have been described previously: pSG5-SRC-1e (36), pSVAR LBD (amino acids 1–653) (37), pGAD424-ARNTD, and pGAD424-ARLBD (38).”
Cited by
Ailanthone targets p23 to overcome MDV3100 resistance in castration-resistant prostate cancer
He, Y., Peng, S., Wang, J., Chen, H., Cong, X., Chen, A., Hu, M., Qin, M., Wu, H., Gao, S., et al. (2016) · Nature Communications · doi:10.1038/ncomms13122 · Cited by 113
The Link Between Androgen Receptor Splice Variants and Castration-Resistant Prostate Cancer
Sprenger, C. C. T., & Plymate, S. R. (2014) · Hormones and Cancer · doi:10.1007/s12672-014-0177-y · Cited by 99
“Because the Hsp90 binding site is located in exon 7, the AR-Vs are not tethered by this Hsp in the cytoplasm and may be transported directly to the nucleus where they are constitutively active [53].”
Campanella, C., D’Anneo, A., Marino, A., Bavisotto, C. C., Barone, R., Emanuele, S., Cascio, F. L., Mocciaro, E., Fais, S., de Macario, E. C., et al. (2015) · Oncotarget · doi:10.18632/oncotarget.6680 · Cited by 74
Mini-review: Foldosome regulation of androgen receptor action in prostate cancer
Cano, L. Q., Lavery, D. N., & Bevan, C. L. (2013) · Molecular and Cellular Endocrinology · doi:10.1016/j.mce.2013.01.023 · Cited by 81
Self-citation17β-Estradiol and testosterone in sarcopenia: Role of satellite cells
la Colla, A. B., Pronsato, L., Milanesi, L. M., & Vasconsuelo, A. (2015) · Ageing Research Reviews · doi:10.1016/j.arr.2015.07.011 · Cited by 84
“In view of that, these HSPs are able to interact with ERs or AR stabilizating them (Reebye et al., 2012; Zoubeidi et al., 2007).”
Molecular Cochaperones: Tumor Growth and Cancer Treatment
Calderwood, S. K. (2013) · Scientifica · doi:10.1155/2013/217513 · Cited by 68
“p23 could also be involved in the incidence of prostate cancer as a key component of the androgen receptor activity [112].”
BackgroundThe Multiple Roles and Therapeutic Potential of Molecular Chaperones in Prostate Cancer
Hoter, A., Rizk, S. E., & Naim, H. Y. (2019) · Cancers · doi:10.3390/cancers11081194 · Cited by 64
Moving Beyond the Androgen Receptor (AR): Targeting AR-Interacting Proteins to Treat Prostate Cancer
Foley, C., & Mitsiades, N. (2016) · Hormones and Cancer · doi:10.1007/s12672-015-0239-9 · Cited by 65
“Furthermore, it has been suggested that chaperones of the AR might also participate in the regulation of transcriptional complexes on chromatin [83] and that cochaperone p23 may actually help stabilize AR on its hormone response elements, potentiating AR-mediated transcription [84].”
Gillis, J. L., Selth, L. A., Centenera, M. M., Townley, S. L., Sun, S., Plymate, S. R., Tilley, W. D., & Butler, L. M. (2013) · Oncotarget · doi:10.18632/oncotarget.975 · Cited by 61
Pappas, B., Yang, Y., Wang, Y., Kim, K., Chung, H. J., Cheung, M., Ngo, K., Shinn, A. H., & Chan, W. K. (2018) · Biochemical Pharmacology · doi:10.1016/j.bcp.2018.03.015 · Cited by 66
Thakur, M. K., Heilbrun, L. K., Sheng, S., Stein, M. N., Liu, G., Antonarakis, E. S., Vaishampayan, U. N., Dzinic, S. H., Li, X., Freeman, S., et al. (2015) · Investigational New Drugs · doi:10.1007/s10637-015-0307-6 · Cited by 64
“Hsp90 regulates AR by forming a complex with unliganded AR along with co-chaperones to create a foldosome complex [8].”
Eighty Years of Targeting Androgen Receptor Activity in Prostate Cancer: The Fight Goes on
Estébanez‐Perpiñá, E., Bevan, C. L., & McEwan, I. J. (2021) · Cancers · doi:10.3390/cancers13030509 · Cited by 57
Self-citationThe heterogeneity of prostate cancers lacking AR activity will require diverse treatment approaches
Labrecque, M. P., Alumkal, J. J., Coleman, I. M., Nelson, P. S., & Morrissey, C. M. (2021) · Endocrine Related Cancer · doi:10.1530/erc-21-0002 · Cited by 51
Ye, M., Tian, H., Lin, S., Mo, J., Li, Z., Chen, X., & Liu, J. (2020) · Oncology Letters · doi:10.3892/ol.2020.12032 · Cited by 46
“The combi‐ nation of androgens and AR induces the dissociation of AR from HSP90 and stimulates AR phosphorylation to activate the activity of downstream proteins (15).”
BackgroundThe co‐chaperone p23 promotes prostate cancer motility and metastasis
Querol Cano, L., Lavery, D. N., Sin, S., Spanjaard, E., Brooke, G. N., Tilman, J. D., Abroaf, A., Gaughan, L., Robson, C. N., Heer, R., et al. (2015) · Molecular Oncology · doi:10.1016/j.molonc.2014.08.014 · Cited by 33
“Given the effects of p23 upon AR activity (Reebye et al., 2012) and stability (and vice-versa) and since prostate cancer is an AR-driven malignancy, we next investigated whether p23 may also be involved in promoting prostate cancer progression.”
BackgroundMethodInfluentialSelf-citationRole of androgen receptor splice variants in prostate cancer metastasis
Xu, J., & Qiu, Y. (2016) · Asian journal of urology · doi:10.1016/j.ajur.2016.08.003 · Cited by 33
“It is conceivable that the nuclear translocation mechanism of AR-Vs might differ from that of AReFL [8,32,33].”
BackgroundIdentification of Stage-Specific Breast Markers Using Quantitative Proteomics
Shaheed, S., Rustogi, N., Scally, A., et al. (2013) · Journal of Proteome Research · doi:10.1021/pr400662k · Cited by 30
Yu, Z., Peng, Y., Gao, J., Zhou, M., Shi, L., Zhao, F. H., Wang, C., Tian, X., Feng, L., Huo, X., et al. (2023) · Science Advances · doi:10.1126/sciadv.ade0387 · Cited by 28
Rane, A., Rajagopalan, S., Ahuja, M., Thomas, B., Chinta, S. J., & Andersen, J. K. (2018) · NeuroToxicology · doi:10.1016/j.neuro.2018.02.012 · Cited by 23
“An important caveat to the use of gedunin and its derivatives as a treatment for PD is the reported modulatory activity of p23 on certain steroid receptors which could result in unwanted “off-target” effects in non-neuronal tissues which suggest that direct brain targeting may be required (Ros-Bernal et al., 2011; Ree…”
Bharadwaj, S., Lee, K. E., Dwivedi, V. D., Yadava, U., & Kang, S. G. (2019) · Journal of Cellular Biochemistry · doi:10.1002/jcb.29229 · Cited by 19
“Likewise, nuclear p23 protein was also observed to promote the AR activity and binding to chromatin, defined as critical steps for AR signaling and prostate cancer development.(7) Recently, ATP antagonist geldanamycin (GA) was reported to inhibit the p23 protein association with Hsp90.”
BackgroundStochasticity of anticancer mechanisms underlying clinical effectiveness of vorinostat
Omari, N. E., Khalid, A., Makeen, H. A., Alhazmi, H. A., Albratty, M., Mohan, S., Tan, C. S., Ming, L. C., Chook, J. B., & Bouyahya, A. (2024) · Heliyon · doi:10.1016/j.heliyon.2024.e33052 · Cited by 18
“Its activity is essential to ensure that client proteins, such as AR, retain their functional structure, which is particularly relevant in the context of PCs where AR is often overexpressed and implicated in tumor progression [88].”
BackgroundCato, L., Neeb, A., Brown, M. A., & Cato, A. C. B. (2014) · Nuclear Receptor Signaling · doi:10.1621/nrs.12005 · Cited by 17
“It has been shown more recently that p23 enhances AR transactivation function in both the cytoplasm, by increasing AR ligand-binding capacity, possibly via direct interaction, and in the nucleus, by enhancing AR occupancy at target promoters [64].”
BackgroundInfluentialHsp90 Co-chaperones as Drug Targets in Cancer: Current Perspectives
Edkins, A. L. (2016) · Topics in medicinal chemistry · doi:10.1007/7355_2015_99 · Cited by 16
Cha, S., Shin, D. H., Seok, J. R., & Myung, J. (2017) · Experimental Cell Research · doi:10.1016/j.yexcr.2017.07.026 · Cited by 16
Tissue proteomics outlines AGR2 AND LOX5 as markers for biochemical recurrence of prostate cancer
Blanco, G. R., Zeneyedpour, L., Duijvesz, D., et al. (2018) · Oncotarget · doi:10.18632/oncotarget.26342 · Cited by 12
“It is involved in AR binding to chromatin, which is a critical step in AR signalling and PCa development [32, 33].”
BackgroundLi, H., Melnyk, J. E., Fu, B. X. H., Shrestha, R., Zhang, M., Sjöström, M., Feng, S., Anderson, J. A., Han, W., Chesner, L. N., et al. (2025) · Nature Genetics · doi:10.1038/s41588-025-02388-8 · Cited by 10
“PTGES3 is reported to have a cytosolic HSP90-dependent protein chaperone function for steroid nuclear receptors, but its activity in PCa is poorly characterized 41,43–46 .”
Madon-Simon, M., Grad, I., Bayo, P., Pérez, P., & Picard, D. (2017) · PLoS ONE · doi:10.1371/journal.pone.0180035 · Cited by 10
“p23 levels may be upregulated in certain types of cancer [57,58] and by ischemia [59], and downregulated in atherosclerotic plaques [60].”
BackgroundPTGES3 proteolysis using the liposomal peptide-PROTAC approach
Liu, S., Yuan, F., Dong, H., Zhang, J., Mao, X., Liu, Y., & Li, H. (2024) · Biology Direct · doi:10.1186/s13062-024-00580-0 · Cited by 8
“For example, in human prostate tumors, the high PTGES3 expression and its ability to promote the acquisition of a more aggressive phenotype have been confirmed, supporting the practicality of PTGES3 as a promising therapeutic target in prostate cancer [21, 22].”
Al-kaabi, M. M., Bakir, W. A.-E., & Gaidan, H. (2020) · Indian Journal of Pathology and Microbiology · doi:10.4103/ijpm.ijpm_460_19 · Cited by 8
Impact of Co-chaperones and Posttranslational Modifications Toward Hsp90 Drug Sensitivity
Backe, S. J., Woodford, M. R., Ahanin, E. F., Sager, R., Bourboulia, D., & Mollapour, M. (2022) · Sub-cellular biochemistry/Subcellular biochemistry · doi:10.1007/978-3-031-14740-1_11 · Cited by 11
Effect of PTGES3 on the Prognosis and Immune Regulation in Lung Adenocarcinoma
Jiang, W., Wei, Q., Xie, H., Wu, D., He, H., & Lv, X. (2023) · Analytical Cellular Pathology · doi:10.1155/2023/4522045 · Cited by 7
Zhang, W., Peng, Y., Zhou, M., Qian, L., Che, Y., Chen, J., Zhang, W., He, C., Qi, M., Shu, X. H., et al. (2025) · Acta Pharmaceutica Sinica B · doi:10.1016/j.apsb.2025.03.048 · Cited by 5
Zhang, J., Tan, K., Meng, X., Yang, W., Wei, H., Sun, R., Yin, L., & Pu, Y. (2015) · International Journal of Environmental Research and Public Health · doi:10.3390/ijerph120911241 · Cited by 5
“The increase in HSP90 may inhibit tumor cell apoptosis and promote cancer development [36].”
BackgroundMolecular biology of castration-resistant prostate cancer: basis for the novel therapeutic targets.
Mellado, B., Marín‐Aguilera, M., & Pereira, M. V. (2013) · PubMed · Cited by 6
Chen, J., Peng, Y., Zhou, M., Che, Y., Zhao, S., He, C., Zhang, W., Tian, X., Zhang, W., Liu, Z., et al. (2025) · Molecular Cancer · doi:10.1186/s12943-025-02439-y · Cited by 10
“Given that p23 has been previously identified as a cochaperone of HSP90 [43, 44], we investigated whether p23-mediated inactivation of the CMA pathway is dependent on HSP90.”
Bhoir, S., & Benedetti, A. D. (2024) · Cancers · doi:10.3390/cancers17010075 · Cited by 3
Avşar, E. (2013) · Royal Society of Chemistry eBooks · doi:10.1039/9781849739689-00336 · Cited by 1
Molecular Chaperones and Co-chaperones as Therapeutic Targets for Cancer
Ahmad, A., & Muzaffar, M. (2016) · Journal of Molecular Pharmaceutics & Organic Process Research · doi:10.4172/2329-9053.1000e124 · Cited by 1
“P23 is among many of Hsp90 co-chaperone that is overexpressed in breast cancer [18], is involved in prostate cancer through androgen receptor activity [19] and is overexpressed in acute lymphoblastic leukemia where it inhibits chemotherapy-induced apoptosis [20].”
BackgroundEmergence and Characterization of the p23 Molecular Chaperone
Echtenkamp, F., & Freeman, B. (2014) · Springer eBooks · doi:10.1007/978-1-4939-1130-1_9 · Cited by 1
“following an elevation in p23 levels [171, 172].”
Kapic, A., Zaman, K., Nguyen, V., Prókai-Tátrai, K., & Prókai, L. (2024) · Pharmaceuticals · doi:10.3390/ph17111508 · Cited by 1
Vaccinia virus requires heat-shock proteins for genome replication and virion assembly
Mok, H. G. W. (2019) · UCL Discovery (University College London) · Cited by 2
Identifying Molecular Chaperones as Therapeutic Targets for Cancer: A Mini Review
Ahmad, A., Farwell, M. A., & Muzaffar, M. (2017) · Biochemistry & Pharmacology Open Access · doi:10.4172/2167-0501.1000224
“P23 is overexpressed in breast cancer [67], is involved in prostate cancer through androgen receptor activity [68] and is overexpressed in acute lymphoblastic leukemia where it inhibits chemotherapy-induced apoptosis [69].”
BackgroundMechanistic Study of p23-Mediated Aryl Hydrocarbon Receptor Expression
Pappas, B. (2018) · Scholarly Commons (University of the Pacific)
da Silva, L. F. (2019) · Digital Library of Theses and Dissertations (Universidade de São Paulo) · doi:10.11606/t.95.2019.tde-19042019-201105
(2013) · Current Opinion in Urology · doi:10.1097/mou.0b013e3283605159
Brooke, G. N., Leach, D. A., Culley, R. L., Azadova, A., Latonen, L., Rees, E., Alkheilewi, M., Pine, A. C., Fioretti, F. M., Reader, C. S., et al. (2026) · Oncogene · doi:10.1038/s41388-026-03682-3 · Cited by 1
Self-citation
Metadata
- Authors
- Reebye, V., Querol Cano, L., Lavery, D. N., Brooke, G. N., Powell, S. M., Chotai, D., Walker, M. M., Whitaker, H. C., Wait, R., Hurst, H. C., & Bevan, C. L.
- Affiliations
- Queen Mary University of London (GB)
- Androgen Signalling Laboratory (V.R., L.Q.C., G.N.B., S.M.P., D.N.L., D.C., C.L.B.), Department of Surgery & Cancer, Imperial College London, London W12 0NN, United Kingdom;
- Venue
- Molecular Endocrinology
- Publisher
- The Endocrine Society
- Published
- 2012-10-01
- Volume
- 26
- Issue
- 10
- Pages
- 1694-1706
- ISSN
- 0888-8809 (ISSN-L)
- 1944-9917
- PMC
- PMC5416955
- OpenAlex
- W2154329747
- Semantic Scholar
- e7e99834a7409b925b516324eecbbe4862df9d5d
- Cited by
- 47
- References
- 70
- Citations by year
- 2026: 1 · 2025: 3 · 2024: 4 · 2023: 2 · 2022: 1 · 2021: 2 · 2020: 2 · 2019: 4 · 2018: 4 · 2017: 3 · 2016: 5 · 2015: 4 · 2014: 5 · 2013: 7
- FWCI
- 4.12
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Locations
- Molecular Endocrinology (publishedVersion)
- Europe PMC (PubMed Central) (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- Open Access at Essex (University of Essex) (acceptedVersion)
- UCL Discovery (University College London) (submittedVersion)
- Funders
- Cancer Research UK
- Imperial College London
- Université de Genève
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Prostate Cancer Treatment and Research
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Heat shock proteins research
- Health Sciences › Medicine › Reproductive Medicine › Sperm and Testicular Function
- Keywords
- p23, androgen receptor, HSP90, co-chaperones, prostate cancer, castration-resistant prostate cancer, therapeutic target
- MeSH terms
- Prostaglandin-E Synthases, Animals, Cell Line, Cell Nucleus, Chlorocebus aethiops, Enhancer Elements, Genetic, Humans, Male, Prostatic Neoplasms, Protein Binding, Receptors, Androgen, Receptors, Glucocorticoid, Transcriptional Activation, Gene Expression, Prostate-Specific Antigen, HSP90 Heat-Shock Proteins, Intramolecular Oxidoreductases, Two-Hybrid System Techniques, Tissue Array Analysis
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.